Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.78 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 12/20 | 0.51 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.50 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17737261 | 1.00 | IDO1 (0.78) | IDO1EPHX2NAMPTNPC1RAB9A | |
| SCHEMBL17737013 | 1.00 | IDO1 (0.78) | IDO1EPHX2NAMPTNPC1RAB9A | |
| SCHEMBL20838748 | 0.91 | IDO1 (0.82) | IDO1EPHX2NAMPTNPC1RAB9A | |
| SCHEMBL17737334 | 0.91 | IDO1 (0.82) | IDO1EPHX2NAMPTNPC1RAB9A | |
| SCHEMBL17731110 | 0.89 | IDO1 (0.78) | IDO1EPHX2NAMPTNPC1RAB9A | |
| SCHEMBL20838710 | 0.88 | EPHX2 (0.62) | IDO1EPHX2NAMPTNPC1RAB9A | |
| SCHEMBL17731111 | 0.88 | EPHX2 (0.62) | IDO1EPHX2NAMPTNPC1RAB9A | |
| SCHEMBL20838648 | 0.88 | IDO1 (1.00) | IDO1EPHX2NAMPTNPC1RAB9A | |
| SCHEMBL20838713 | 0.88 | IDO1 (0.76) | IDO1EPHX2NAMPTNPC1RAB9A | |
| SCHEMBL20838647 | 0.88 | IDO1 (1.00) | IDO1EPHX2NAMPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | claimed |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2022-09-01 | — | — | US | claimed |
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11242319-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242319-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2019-03-28 | — | — | US | disclosed |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242319-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | IDO1 1/4885EPHX2 611/4885NAMPT 457/4885 |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | IDO1 1/4885EPHX2 611/4885NAMPT 457/4885 |
| US-11932601-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | IDO1 1/4885EPHX2 611/4885NAMPT 457/4885 |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | IDO1 1/4885EPHX2 611/4885NAMPT 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.